669 Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer

• Gady Cojocaru,
• Inbal Barbiro,
• Amita Patnaik,
• Manish Sharma,
• Drew Rasco,
• Benjamin Izar,
• Kyriakos P Papadopoulos,
• Eran Ophir,
• Ryan Sullivan,
• Pierre Ferre,
• Stéphanie Gaillard,
• Daniel Vaena,
• Oladapo Yeku,
• John Moroney,
• Adeboye H Adewoye

Affiliations

Gady Cojocaru

Compugen Ltd., Holon, Israel

Inbal Barbiro

10Compugen Ltd., Holon, Israel

Amita Patnaik

Aff107 grid.477989.c0000000404347503South Texas Accelerated Research Therapeutics, LLC San Antonio TX USA

Manish Sharma

8START Midwest, Chicago, IL, USA

Drew Rasco

2The START Center for Cancer Care, San Antonio, TX, USA

Benjamin Izar

Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USA

Kyriakos P Papadopoulos

5START San Antonio, San Antonio, TX, USA

Eran Ophir

1Compugen Ltd., Holon, Israel

Ryan Sullivan

7Massachusetts General Hospital, -, Boston, USA

Pierre Ferre

3Compugen, Toulouse, France

Stéphanie Gaillard

Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC.

Daniel Vaena

4West Cancer Center and Research Institute, Germantown, TN, USA

Oladapo Yeku

1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

John Moroney

7University of Chicago Medicine, Chicago, USA

Adeboye H Adewoye

12Compugen USA Inc., San Francisco, CA, USA